Pulmonary toxicity may stem from the combination of brentuximab vedotin with bleomycin or gemcitabine. Non-bleomycin containing drug regimens may not induce pulmonary toxicity (PMID 24239220)
v2.2
Pulmonary toxicity may stem from the combination of brentuximab vedotin with bleomycin or gemcitabine. Non-bleomycin containing drug regimens may not induce pulmonary toxicity (PMID 24239220)